+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Plasma Fractionation Market - Forecasts from 2021 to 2026

  • PDF Icon


  • 124 Pages
  • December 2021
  • Region: Global
  • Knowledge Sourcing Intelligence LLP
  • ID: 5547612
The plasma fractionation market is expected to grow at a compound annual growth rate of 7.21% over the forecast period to reach a market size of US$35.405 billion in 2026, from US$21.748 billion in 2019. The market is expected to surge in the coming years, due to the rise in the prevalence rate of chronic diseases, the increasing rate of the geriatric population, and other related factors. The surge in the development of diagnostic and healthcare facilities is also anticipated to facilitate market growth, in the coming years. However, the high cost of plasma derivatives is one of the major factors, that could hinder the market growth in low developing nations.

North America is expected to have a major share in the market, due to the rise in the research and development intending in the development of novel solutions. The presence of some of the major players in the region is also expected to facilitate market growth. In the coming years, Asia Pacific is also expected to register a significant CAGR, due to the increase in the development of novel and advanced healthcare and diagnostic facilities.

Increasing prevalence rate of chronic diseases

The market is expected to surge in the coming years, due to the rising prevalence rate of chronic diseases, worldwide. According to the data given by the Food & Agriculture Organisation and the World Health Organisation, it was estimated and projected that chronic diseases would account for around 3/4 of all deaths, globally, by the year 2020. The plasma fractionation market is expected to surge, as the rate of chronic diseases has been accelerating at a considerable rate.

The rising popularity of blood plasma fractionation

There has been a surge in the popularity of blood plasma fractionation, worldwide, in the past few years. Blood usually comprises about 55% plasma, and around 44% red blood cells. The demand is expected to surge, due to the rise in the number of blood banks, as the blood is collected and then the plasma is separated to complete the process called blood plasma fractionation. There has also been a surge in the therapeutic uses of blood plasma fractionation, which is expected to play a major role in the market growth. According to the data given by the Government of India, there are around 2,700 blood banks in the nation, that have been collecting around 10 million units of blood, per year. These trends are projected to play a considerable role in the market growth, in the coming years.

Competitive Analysis

There have been several players that have been offering plasma fractionation solutions for their customers. For instance, Octapharma, one of the imperative players in the market, has been collecting plasma from donors and then producing it into a life-saving therapy. The company had stated that their plasma-derived therapy had been completely purified, monitored, controlled, and inspected before the use. Other players, such as GE Healthcare and CSL Ltd., are also expected to play a key role in the market growth, in the coming years.


By Application

  • Neurology
  • Immunology
  • Hematology
  • Pulmonology

By End-User

  • Hospitals & Clinics
  • Academic & Research Institutes

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Thailand
  • Taiwan
  • Indonesia
  • Others

Table of Contents

1. Introduction
1.1. Market Overview
1.2. COVID-19 Scenario
1.3. Market Definition
1.4. Market Segmentation
2. Research Methodology
2.1. Research Data
2.2. Assumptions
3. Executive Summary
3.1. Research Highlights
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. Plasma Fractionation Market Analysis, By Application
5.1. Introduction
5.2. Neurology
5.3. Immunology
5.4. Hematology
5.5. Pulmonology
6. Plasma Fractionation Market Analysis, By End User
6.1. Introduction
6.2. Hospitals & Clinics
6.3. Academic & Research Institutes
7. Plasma Fractionation Market Analysis, By Geography
7.1. Introduction
7.2. North America
7.2.1. United States
7.2.2. Canada
7.2.3. Mexico
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Others
7.4. Europe
7.4.1. UK
7.4.2. France
7.4.3. Germany
7.4.4. Spain
7.4.5. Others
7.5. Middle East and Africa
7.5.1. Saudi Arabia
7.5.2. UAE
7.5.3. Israel
7.5.4. Others
7.6. Asia Pacific
7.6.1. Japan
7.6.2. China
7.6.3. India
7.6.4. South Korea
7.6.5. Thailand
7.6.6. Taiwan
7.6.7. Indonesia
7.6.8. Others
8. Competitive Environment and Analysis
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
9. Company Profiles
9.1. Octapharma AG
9.2. GE Healthcare
9.3. Merck KGaA
9.4. Grifols SA
9.5. CSL Ltd.
9.6. Biotest
9.7. Sanquin
9.8. Takeda Pharmaceutical Company
9.9. Kedrion
9.10. Bio Products Laboratory

Companies Mentioned

  • Octapharma AG
  • Grifols SA
  • CSL Ltd.
  • Tiancheng (Germany) Pharmaceutical Holdings AG
  • Sanquin
  • Shire PLC
  • Kedrion Biopharma
  • Bio Products Laboratory
  • China Biologic



Table Information